David Anderson

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Alize J Ferrari, Damian Santomauro, Amirali Aali et al. · The Lancet · 2024 · 3.7K citations · Full text

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Mohsen Naghavi, Kanyin Liane Ong, Amirali Aali et al. · The Lancet · 2024 · 2.1K citations · Full text

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess et al. · The Lancet Neurology · 2024 · 1.4K citations · Full text

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Hazim Ababneh, Yohannes Habtegiorgis Abate, Cristiana Abbafati et al. · The Lancet · 2024 · 790 citations · Full text

Global Burden, Infectious Disease Epidemiology, Forecasting Analysis +13

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7